Sugi Predict

Sugi Predict / Targets / EWSR1

EWSR1

RNA-binding protein EWS · Q01844 · EWSR1 on Sugi Atlas →

491 patent compounds predicted against EWSR1, 357 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15337231 SCHEMBL15337231 1.00 6/20
SCHEMBL15337266 SCHEMBL15337266 1.00 6/20
SCHEMBL15337280 SCHEMBL15337280 1.00 6/20
SCHEMBL17679814 SCHEMBL17679814 1.00 6/20
SCHEMBL17679816 SCHEMBL17679816 1.00 6/20
SCHEMBL25140493 SCHEMBL25140493 0.80 6/20
SCHEMBL15337268 SCHEMBL15337268 0.78 6/20
SCHEMBL22199725 SCHEMBL22199725 0.77 6/20
SCHEMBL15337274 SCHEMBL15337274 0.75 6/20
SCHEMBL19419580 SCHEMBL19419580 0.75 6/20
SCHEMBL19620144 SCHEMBL19620144 0.75 6/20
SCHEMBL19424045 SCHEMBL19424045 0.73 6/20
SCHEMBL13253323 SCHEMBL13253323 0.73 6/20
SCHEMBL13253325 SCHEMBL13253325 0.73 6/20
SCHEMBL13253326 SCHEMBL13253326 0.73 6/20
SCHEMBL13253331 SCHEMBL13253331 0.73 6/20
SCHEMBL17669239 SCHEMBL17669239 0.73 6/20
SCHEMBL17679855 SCHEMBL17679855 0.73 6/20
SCHEMBL17679856 SCHEMBL17679856 0.73 6/20
SCHEMBL29810788 SCHEMBL29810788 0.73 6/20

Clinical trials — most relevant to EWSR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma PHASE3ACTIVE_NOT_RECRUITING
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas PHASE1/PHASE2RECRUITING
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Lurbinectedin in FET-Fused Tumors PHASE1/PHASE2RECRUITING
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors PHASE2ACTIVE_NOT_RECRUITING
First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3) PHASE2COMPLETED
Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas PHASE2COMPLETED
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma PHASE1/PHASE2RECRUITING
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma PHASE2ACTIVE_NOT_RECRUITING
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma PHASE2COMPLETED
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults PHASE2COMPLETED
Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors PHASE2ACTIVE_NOT_RECRUITING
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma PHASE1COMPLETED
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) PHASE1RECRUITING
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas PHASE1UNKNOWN
Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma nanCOMPLETED
Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1 nanCOMPLETED
Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives nanCOMPLETED
Circulating Tumor DNA in Soft Tissue Sarcoma nanRECRUITING
Observational Study on Skeletal Ewing's Sarcoma nanRECRUITING
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma nanCOMPLETED
Biomarker in Tissue Samples From Patients With Ewing Sarcoma nanCOMPLETED
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study nanACTIVE_NOT_RECRUITING
Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults nanCOMPLETED
Study on Dynamic CtDNA Analysis in Pediatric Soft Tissue Sarcoma nanUNKNOWN
Biomarkers in Tissue Samples From Patients With Ewing Sarcoma nanCOMPLETED
Molecular Analysis Of Solid Tumors nanRECRUITING
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a EWSR1 binder may also engage these)

ProteinNameSimilarity
Q61545 — 1.000 Q61545 →
FUS RNA-binding protein FUS 0.989 landscape →
Q28009 — 0.987 Q28009 →
P56959 — 0.986 P56959 →
Q5RFQ1 — 0.977 Q5RFQ1 →
Q22037 — 0.976 Q22037 →
Q5RBU8 — 0.976 Q5RBU8 →
Q8VIJ6 — 0.976 Q8VIJ6 →
P48809 — 0.976 P48809 →
P48810 — 0.975 P48810 →
DAZAP1 DAZ-associated protein 1 0.975 landscape →
Q4P2Q5 — 0.975 Q4P2Q5 →
A7VJC2 — 0.975 A7VJC2 →
P51992 — 0.975 P51992 →
SFPQ Splicing factor, proline- and glutamine-rich 0.974 landscape →
Q63627 — 0.974 Q63627 →
Q99383 — 0.974 Q99383 →
Q94KD0 — 0.974 Q94KD0 →
Q6NWC6 — 0.974 Q6NWC6 →
Q7SAX8 — 0.974 Q7SAX8 →
Q9JMD0 — 0.974 Q9JMD0 →
Q7ZWA3 — 0.973 Q7ZWA3 →
Q4R7F0 — 0.973 Q4R7F0 →
Q0P5D2 — 0.973 Q0P5D2 →
Q5R8K4 — 0.973 Q5R8K4 →
HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like protein 1 0.972 landscape →
Q9JII5 — 0.972 Q9JII5 →
Q6DDW4 — 0.972 Q6DDW4 →
ZNF207 BUB3-interacting and GLEBS motif-containing protein ZNF207 0.972 landscape →
Q8VDM6 — 0.972 Q8VDM6 →